Even if they require labs and implement monitoring, Narang believes weight loss clinics offering compounded semaglutide are, absolutely taking advantage of peoples desperation to lose weight. Theres zero research behind what theyre saying
GLP-1 Vision Side Effects: If they notice patterns of negative events, especially serious complications like vision loss, they will review whether the existing product labeling effectively communicates these risks to healthcare providers and patients
These side effects are usually temporary and go away as your body adjusts to the medication
New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound
The semaglutide plateau guide , why you are not losing weight on semaglutide , and why you are not losing weight on tirzepatide cover proven strategies for breaking through stalls
